Sort   by:  
 Page size 
UnknownComparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
Not available
S-EPMC3462046 | biostudies-literature
ProteomicsProteomic Landscape of Endoplasmic Reticulum Remodeling During Neurogenesis via Combinatorial Selective ER-phagy
The endoplasmic reticulum (ER) functions in protein and lipid synthesis, calcium ion flux, and inter-organelle communication, all of which are driven by the ER proteome landscape. ER is remodeled in part through autophagy-dependent protein turnover involving membrane-embedded ER-phagy receptors1,2. ...
ORGANISM(S): Homo sapiens (Human) 
2024-01-08 | PXD041069 | Pride
Selective autophagy Er-phagy Human induced neurons Tmt 18-plex 
ProteomicsProteomic Landscape of Endoplasmic Reticulum Remodeling During Neurogenesis via Combinatorial Selective ER-phagy
The endoplasmic reticulum (ER) functions in protein and lipid synthesis, calcium ion flux, and inter-organelle communication, all of which are driven by the ER proteome landscape. ER is remodeled in part through autophagy-dependent protein turnover involving membrane-embedded ER-phagy receptors1,2. ...
ORGANISM(S): Homo sapiens (Human) 
2024-01-08 | PXD046646 | Pride
Selective autophagy Er-phagy Human induced neurons Tmt 18-plex 
UnknownPartial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-bet<sup>+</sup> B cells.
Not available
S-EPMC9355881 | biostudies-literature
UnknownWhole-genome sequencing of a sporadic primary immunodeficiency cohort.
Not available
S-EPMC7334047 | biostudies-literature
UnknownRare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.
Not available
S-EPMC10074346 | biostudies-literature
UnknownX-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.
Not available
S-EPMC8532080 | biostudies-literature
UnknownInborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Not available
S-EPMC7857407 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
Sort   by:  
 Page size